90824-33-2

Usage

Uses

Used in Pharmaceutical Development:
Benzenesulfonamide, 2-hydrazino(9CI) is utilized as a key component in the development of pharmaceuticals. Its unique structure and properties contribute to the creation of new drugs with potential therapeutic effects.
Used in Organic Synthesis:
Benzenesulfonamide, 2-hydrazino(9CI) serves as a valuable building block in the synthesis of new and useful organic compounds. Its versatility in chemical reactions allows for the production of a wide range of products.
Used in Medicinal Chemistry:
Benzenesulfonamide, 2-hydrazino(9CI) is employed as a precursor for the synthesis of other organic compounds, particularly in the field of medicinal chemistry. Its ability to participate in various chemical reactions makes it an essential tool for researchers.
Used in Anti-Cancer Research:
Benzenesulfonamide, 2-hydrazino(9CI) has been studied for its potential as an anti-cancer agent. Its unique properties may contribute to the development of new treatments for various types of cancer.
Used in Autoimmune Disease Therapy:
Benzenesulfonamide, 2-hydrazino(9CI) has also been investigated for its potential as a therapeutic agent for autoimmune diseases. Its ability to modulate immune responses could lead to new approaches in managing these conditions.

Upstream product

• 3306-62-5 2-AMINOBENZENESULFONAMIDE 

Downstream Products

• 885022-13-9 2-[6-(4-iodo-phenyl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl]-benzenesulfonamide 
• 885022-11-7 2-[6-(2'-methylsulfanyl-biphenyl-4-yl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl]-benzenesulfonamide 
• 915306-34-2 2-[6-(2'-formyl-biphenyl-4-yl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl]-benzenesulfonamide 

Relevant academic research and scientific papers

Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties

The bicyclic dihydropyrazolopyridinone scaffold allowed for incorporation of multiple P1 moieties with subnanomolar binding affinities for blood coagulation factor Xa. The compound 3-[6-(2′-dimethylaminomethyl-biphenyl-4-yl)-7-oxo-3-trifluoro-methyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridine-l-yl]-benzamide 6d shows good fXa potency, selectivity, in vivo efficacy and oral bioavailability. Compound 6d was selected for further pre-clinical evaluations.

Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties

Targeting proteins overexpressed in hypoxic tumors is as an important means of controlling cancer disease. One such protein is the carbonic anhydrase (CA) isoenzyme IX, which in some types of tumors is overexpressed 150-200-fold. We report here a series of sulfonamide derivatives, prepared from 2-carbohydrazido- and 4-carbohydrazido-benzenesulfonamides, which were further derivatized by reaction with aryl isocyanates or arylsulfonyl isocyanates. Several low nanomolar CA IX inhibitors were detected in this way. SAR is discussed for the diverse types of inhibitors and their affinity for different isozymes, with the aim of obtaining isozyme-specific CA IX inhibitors, with putative applications as antitumor drugs.